Amylyx Pharmaceuticals
NASDAQ · AMLX·Cambridge, MA·Small-cap·Phase 3
Clinical-stage biotech focused on novel therapies for serious endocrine and neurodegenerative diseases. Lead asset avexitide is a GLP-1 receptor antagonist in Phase 3 LUCIDITY for post-bariatric hypoglycemia (enrollment complete). Pipeline also includes AMX0035 in Wolfram syndrome and progressive supranuclear palsy, and AMX0114 (anti-calpain-2 ASO) for ALS.
Decks (1)
| Title | Occasion | Date | Slides | Source |
|---|---|---|---|---|
| Amylyx Pharmaceuticals Corporate Presentation — March 2026 | Corporate overview | March 24, 2026 | 41 |